Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: Fred Levine who wrote (2324)	9/4/2002 12:48:59 PM
From: 613	Read Replies (1) \| Respond to of 2515

What do you mean when you say the Euro trials are going ahead 'nicely'? Won't the results be known only after they are completed? Also, even though they currently have cash, won't they be paying BILLIONS to settle lawsuits?

To: Fred Levine who wrote (2324)	9/4/2002 1:15:48 PM
From: tuck	Respond to of 2515

In addition to concerns raised in the previous post, IMCL's lead over competing drugs that work as well or better has shrunk since the fiasco. For instance ABX-EGF. Abgenix might be able to learn from the PIII trial blunders to date (erbitux, Iressa), as well. Abgenix looks more attractive to me, and I recently went long for a small position trade. I think ABX-EGF is the best Mab in the EGFr class out there in relatively advanced development. Cheers, Tuck